Clinical trial
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With…
NCT00399035 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00399035 |
|---|---|
| Title | Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer |
| Official title | A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients… |
| Acronym | HORIZON II |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin), Cediranib Placebo |
| Enrollment | 1,254 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Aug 1, 2016 |
| First posted | Nov 14, 2006 |
| Last update posted | Dec 28, 2016 |
| Countries | Argentina, Australia, Brazil, Bulgaria, China, Czechia, Germany, Hungary, India, Philippines, Poland, South Korea and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: